Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert L Findling

Showing results (311-320 of 423) with videos related to

Pageof 43
Sort By:
Journal of Clinical Psychopharmacology|June 28, 2021
A Phase 3, Placebo-Controlled Trial of Once-Daily Viloxazine Extended-Release Capsules in Adolescents With Attention-Deficit/Hyperactivity DisorderAzmi Nasser, Tesfaye Liranso, Toyin Adewole, et al.
Appetite|April 15, 2024
Parental perceptions of body weight and appetite in infants and toddlers with cystic fibrosisSarah Ann Duck, Elena Jansen, Afroditi Papantoni, et al.
Journal of the American Academy of Child and Adolescent Psychiatry|October 10, 2020
Generalizing the Prediction of Bipolar Disorder Onset Across High-Risk PopulationsAnna R Van Meter, Danella M Hafeman, John Merranko, et al.
The Journal of Clinical Psychiatry|May 17, 2007
Double-blind, placebo-controlled trial of divalproex monotherapy in the treatment of symptomatic youth at high risk for developing bipolar disorderRobert L Findling, Thomas W Frazier, Eric A Youngstrom, et al.
Clinical Therapeutics|July 30, 2020
A Phase III, Randomized, Placebo-controlled Trial to Assess the Efficacy and Safety of Once-daily SPN-812 (Viloxazine Extended-release) in the Treatment of Attention-deficit/Hyperactivity Disorder in School-age ChildrenAzmi Nasser, Tesfaye Liranso, Toyin Adewole, et al.
Journal of Clinical Psychopharmacology|July 16, 2008
Tolerability and pharmacokinetics of aripiprazole in children and adolescents with psychiatric disorders: an open-label, dose-escalation studyRobert L Findling, Ralph E Kauffman, Floyd R Sallee, et al.
The Journal of Clinical Psychiatry|July 1, 2008
Clinical correlates of patients with rapid-cycling bipolar disorder and a recent history of substance use disorder: a subtype comparison from baseline data of 2 randomized, placebo-controlled trialsKeming Gao, Marcia L Verduin, David E Kemp, et al.
Journal of Child and Adolescent Psychopharmacology|April 18, 2019
Adiposity, Hepatic Triglyceride, and Carotid Intima Media Thickness During Behavioral Weight Loss Treatment in Antipsychotic-Treated Youth: A Randomized Pilot StudyGinger E Nicol, Rachel Kolko, Eric J Lenze, et al.
Bipolar Disorders|October 25, 2011
Pediatric bipolar spectrum disorder and ADHD: comparison and comorbidity in the LAMS clinical sampleL Eugene Arnold, Christine Demeter, Katherine Mount, et al.
Drug Design, Development and Therapy|September 15, 2018
Asenapine pharmacokinetics and tolerability in a pediatric populationPeter Dogterom, Robert Riesenberg, Rik de Greef, et al.
Pageof 43

Showing results (311-320 of 423) with videos related to

Sort By:
Pageof 43
Journal of Clinical Psychopharmacology|June 28, 2021
A Phase 3, Placebo-Controlled Trial of Once-Daily Viloxazine Extended-Release Capsules in Adolescents With Attention-Deficit/Hyperactivity DisorderAzmi Nasser, Tesfaye Liranso, Toyin Adewole, et al.
Appetite|April 15, 2024
Parental perceptions of body weight and appetite in infants and toddlers with cystic fibrosisSarah Ann Duck, Elena Jansen, Afroditi Papantoni, et al.
Journal of the American Academy of Child and Adolescent Psychiatry|October 10, 2020
Generalizing the Prediction of Bipolar Disorder Onset Across High-Risk PopulationsAnna R Van Meter, Danella M Hafeman, John Merranko, et al.
The Journal of Clinical Psychiatry|May 17, 2007
Double-blind, placebo-controlled trial of divalproex monotherapy in the treatment of symptomatic youth at high risk for developing bipolar disorderRobert L Findling, Thomas W Frazier, Eric A Youngstrom, et al.
Clinical Therapeutics|July 30, 2020
A Phase III, Randomized, Placebo-controlled Trial to Assess the Efficacy and Safety of Once-daily SPN-812 (Viloxazine Extended-release) in the Treatment of Attention-deficit/Hyperactivity Disorder in School-age ChildrenAzmi Nasser, Tesfaye Liranso, Toyin Adewole, et al.
Journal of Clinical Psychopharmacology|July 16, 2008
Tolerability and pharmacokinetics of aripiprazole in children and adolescents with psychiatric disorders: an open-label, dose-escalation studyRobert L Findling, Ralph E Kauffman, Floyd R Sallee, et al.
The Journal of Clinical Psychiatry|July 1, 2008
Clinical correlates of patients with rapid-cycling bipolar disorder and a recent history of substance use disorder: a subtype comparison from baseline data of 2 randomized, placebo-controlled trialsKeming Gao, Marcia L Verduin, David E Kemp, et al.
Journal of Child and Adolescent Psychopharmacology|April 18, 2019
Adiposity, Hepatic Triglyceride, and Carotid Intima Media Thickness During Behavioral Weight Loss Treatment in Antipsychotic-Treated Youth: A Randomized Pilot StudyGinger E Nicol, Rachel Kolko, Eric J Lenze, et al.
Bipolar Disorders|October 25, 2011
Pediatric bipolar spectrum disorder and ADHD: comparison and comorbidity in the LAMS clinical sampleL Eugene Arnold, Christine Demeter, Katherine Mount, et al.
Drug Design, Development and Therapy|September 15, 2018
Asenapine pharmacokinetics and tolerability in a pediatric populationPeter Dogterom, Robert Riesenberg, Rik de Greef, et al.
Pageof 43